Event-Driven Stocks

SPECTRUM PHARMACEUTICALS INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs5 warning2 severedetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue$10.1M$0$0$0$0$0
Operating income−$72.7M−$147.7M−$169.7M−$37.8M−$30.0M−$116.3M
Net income−$75.4M−$158.6M−$160.9M−$112.7M−$19.2M−$92.2M
Total assets$103.3M$111.5M$196.8M$263.4M$390.9M$487.4M
Total liabilities$75.5M$64.0M$62.6M$73.0M$119.5M$136.1M
Equity$27.9M$47.6M$134.2M$190.4M$271.4M$351.3M
EPS (diluted)$-0.41$-1.02$-1.29$-1.16$-1.07
Shares out.177.2M153.7M113.7M111.0M102.7M80.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
−718.8%
Net margin
−745.5%
Return on equity
−270.4%
Return on assets
−73.0%
Return on capital (ROCE)
−119.9%
Liabilities / assets
73.0%
Debt / equity
2.71×
Book value / share
$0.16
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
-35.95distress
Accruals / assets
20.9%high accruals
Piotroski F-Score
3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
21
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 0Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

2 severe5 warning0 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)